- KR₩125bn
- KR₩145bn
- KR₩144bn
Annual income statement for CTC Bio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 130,032 | 140,318 | 165,206 | 137,878 | 144,407 |
| Cost of Revenue | |||||
| Gross Profit | 26,629 | 33,497 | 54,551 | 43,066 | 53,282 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 136,972 | 145,188 | 162,406 | 151,868 | 148,025 |
| Operating Profit | -6,940 | -4,870 | 2,799 | -13,989 | -3,618 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22,738 | -7,687 | 199 | -15,715 | -5,319 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22,868 | -7,978 | 4,704 | -15,588 | -5,220 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -19,458 | -7,318 | 4,704 | -15,588 | -5,220 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19,458 | -7,318 | 4,704 | -15,588 | -5,220 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,023 | -273 | 429 | -403 | -230 |
| Dividends per Share |